287 related articles for article (PubMed ID: 25348907)
1. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
Tuchscherer RM; Nair K; Ghushchyan V; Saseen JJ
Am J Cardiovasc Drugs; 2015 Feb; 15(1):27-34. PubMed ID: 25348907
[TBL] [Abstract][Full Text] [Related]
2. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
3. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
Karimi S; Hough A; Beckey C; Parra D
J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676
[TBL] [Abstract][Full Text] [Related]
4. Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing.
Prom R; Umscheid CA; Kasbekar N; Spinler SA
Am J Health Syst Pharm; 2013 Nov; 70(21):1878-9. PubMed ID: 24128959
[No Abstract] [Full Text] [Related]
5. Impact of pharmacists' interventions and simvastatin dose restrictions.
Shoulders BR; Franks AS; Barlow PB; Williams JD; Farland MZ
Ann Pharmacother; 2014 Jan; 48(1):54-61. PubMed ID: 24259645
[TBL] [Abstract][Full Text] [Related]
6. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
[TBL] [Abstract][Full Text] [Related]
7. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm.
Finks SW; Campbell JD
Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension.
Savage RD; Visentin JD; Bronskill SE; Wang X; Gruneir A; Giannakeas V; Guan J; Lam K; Luke MJ; Read SH; Stall NM; Wu W; Zhu L; Rochon PA; McCarthy LM
JAMA Intern Med; 2020 May; 180(5):643-651. PubMed ID: 32091538
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with statin selection among privately insured commercial and Medicare patients.
Zhao Z; Bae J; Sponseller CA; Zhu Y; Kryzhanovski VA; LeNarz LA
Curr Med Res Opin; 2013 Apr; 29(4):395-404. PubMed ID: 23406054
[TBL] [Abstract][Full Text] [Related]
11. Does simvastatin cause more myotoxicity compared with other statins?
Backes JM; Howard PA; Ruisinger JF; Moriarty PM
Ann Pharmacother; 2009 Dec; 43(12):2012-20. PubMed ID: 19920157
[TBL] [Abstract][Full Text] [Related]
12. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
13. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Devabhaktuni M; Bangalore S
Vasc Health Risk Manag; 2009; 5(1):377-87. PubMed ID: 19475775
[TBL] [Abstract][Full Text] [Related]
14. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
Baser O; Andrews LM; Wang L; Xie L
J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
[TBL] [Abstract][Full Text] [Related]
15. Team-based approach to addressing simvastatin safety concerns.
Robinson M; Gunning K; Pippitt K; McAdam-Marx C; Jennings BT
J Am Pharm Assoc (2003); 2013; 53(5):539-44. PubMed ID: 24030132
[TBL] [Abstract][Full Text] [Related]
16. New simvastatin dosing recommendations.
Med Lett Drugs Ther; 2011 Aug; 53(1370):61-2. PubMed ID: 21836544
[No Abstract] [Full Text] [Related]
17. Statin safety: an assessment using an administrative claims database.
Cziraky MJ; Willey VJ; McKenney JM; Kamat SA; Fisher MD; Guyton JR; Jacobson TA; Davidson MH
Am J Cardiol; 2006 Apr; 97(8A):61C-68C. PubMed ID: 16581331
[TBL] [Abstract][Full Text] [Related]
18. Weighing the benefits of high-dose simvastatin against the risk of myopathy.
Egan A; Colman E
N Engl J Med; 2011 Jul; 365(4):285-7. PubMed ID: 21675881
[No Abstract] [Full Text] [Related]
19. Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics.
Vouri SM; Jiang X; Manini TM; Solberg LM; Pepine C; Malone DC; Winterstein AG
JAMA Netw Open; 2019 Dec; 2(12):e1918425. PubMed ID: 31880802
[TBL] [Abstract][Full Text] [Related]
20. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
Golightly LK; Barber GR; Barron MA; Page RL
Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
